Control of Paneth Cell Fate, Intestinal Inflammation, and Tumorigenesis by PKCλ/ι  by Nakanishi, Yuki et al.
ArticleControl of Paneth Cell Fate, Intestinal Inflammation,
and Tumorigenesis by PKCl/iGraphical AbstractHighlightsd PKCl/i is required for Paneth cell differentiation
d PKCl/i reduces EZH2 stability and promotes Atoh1 and Gfi1
expression
d PKCl/i induces intestinal epithelial cell survival through the
repression of JNK
d PKCl/i loss enhances intestinal inflammation and cancerNakanishi et al., 2016, Cell Reports 16, 3297–3310
September 20, 2016 ª 2016 The Author(s).
http://dx.doi.org/10.1016/j.celrep.2016.08.054Authors
Yuki Nakanishi, Miguel Reina-Campos,
Naoko Nakanishi, ...,
Richard S. Blumberg,Maria T.Diaz-Meco,
Jorge Moscat
Correspondence
jmoscat@sbpdiscovery.org
In Brief
Nakanishi et al. demonstrate that the
atypical PKCl/i is lost in the intestinal
epithelium of Crohn’s disease patients,
and its genetic inactivation in mice results
in defective Paneth cell differentiation,
enhanced JNK activity, and apoptosis in
the intestinal epithelium, which leads to
increased intestinal inflammation and
tumorigenesis.Accession NumbersGSE84118
Cell Reports
ArticleControl of Paneth Cell Fate, Intestinal
Inflammation, and Tumorigenesis by PKCl/i
Yuki Nakanishi,1 Miguel Reina-Campos,1 Naoko Nakanishi,1 Victoria Llado,1 Lisa Elmen,2 Scott Peterson,2 Alex Campos,3
Surya K. De,4 Michael Leitges,5 Hiroki Ikeuchi,6 Maurizio Pellecchia,4 Richard S. Blumberg,7 Maria T. Diaz-Meco,1
and Jorge Moscat1,8,*
1Cancer Metabolism and Signaling Networks Program
2Bioinformatics and Structural Biology Program
3Proteomics Facility
Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
4Division of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, CA 92521, USA
5Biotechnology Centre of Oslo, University of Oslo, 0316 Oslo, Norway
6Department of Surgery, Hyogo College of Medicine, Nishinomiya 663-8131, Japan
7Division of Gastroenterology, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
8Lead Contact
*Correspondence: jmoscat@sbpdiscovery.org
http://dx.doi.org/10.1016/j.celrep.2016.08.054SUMMARY
Paneth cells are a highly specialized population of in-
testinal epithelial cells located in the crypt adjacent
to Lgr5+ stem cells, from which they differentiate
through a process that requires downregulation of
the Notch pathway. Their ability to store and release
antimicrobial peptides protects the host from intesti-
nal pathogens and controls intestinal inflammation.
Here, we show that PKCl/i is required for Paneth
cell differentiation at the level of Atoh1 and Gfi1,
through the control of EZH2 stability by direct phos-
phorylation. The selective inactivation of PKCl/i in
epithelial cells results in the loss of mature Paneth
cells, increased apoptosis and inflammation, and
enhanced tumorigenesis. Importantly, PKCl/i ex-
pression in human Paneth cells decreases with pro-
gression of Crohn’s disease. Kaplan-Meier survival
analysis of colorectal cancer (CRC) patients revealed
that low PRKCI levels correlated with significantly
worse patient survival rates. Therefore, PKCl/i is
a negative regulator of intestinal inflammation and
cancer through its role in Paneth cell homeostasis.
INTRODUCTION
The control of intestinal homeostasis relies on a perfectly orches-
trated balance of interactions among the different cell types of
the intestinal epithelium, microbiota, and immune system (Me-
dema and Vermeulen, 2011). The gut epithelium undergoes
continuous self-renewal from intestinal stem cells (ISCs) located
in the proliferative crypt (van der Flier and Clevers, 2009). Paneth
cells are critical to the control of the ISC niche and the intestinal
barrier (Adolph et al., 2013; Clevers and Bevins, 2013). This is a
highly specialized population of intestinal epithelial cells (IECs)Cell Report
This is an open access article under the CC BY-Nlocated adjacent to Lgr5+ ISC, which differentiate from ISCs
upon downregulation of the Notch pathway (Fre et al., 2005;
van Es et al., 2005). Paneth cells have large granules containing
lysozyme and other peptides, such as defensins/cryptidins, that
serve to protect the host from intestinal pathogens (Clevers and
Bevins, 2013) and play a critical role in the control of intestinal
inflammation (Adolph et al., 2013). Alterations in the normal func-
tion of IECs, especially Paneth cells, contribute to pathologies
like inflammatory bowel diseases (IBDs), including Crohn’s dis-
ease (CD) and ulcerative colitis (UC) (Kaser et al., 2010). Impor-
tantly, patients with IBD are at an increased risk for colorectal
cancer (CRC) (Jess et al., 2006). Patients with CD often exhibit
a reduced number of healthy Paneth cells and decreased
expression of defensins in areas of acute inflammation (Weh-
kamp et al., 2008). Therefore, understanding the signaling cas-
cades that regulate Paneth cell differentiation and function, as
well as their role in the control of intestinal homeostasis and
pathology, is critical for the design of new therapies for these
diseases.
Here, we have addressed this biological problem in the
context of the role and mechanisms of action of protein kinase
C (PKC) l/i. This kinase, along with PKCz, constitutes the atyp-
ical PKC family (Moscat et al., 2009). Both have been implicated
in several oncogenic and inflammatory pathways in vitro, but
their role in intestinal homeostasis and pathology has only
recently begun to be investigated in physiologically relevant
mouse models (Calcagno et al., 2011; Llado et al., 2015; Ma
et al., 2013; Moscat et al., 2009). In this regard, our laboratory
previously reported a specific tumor-suppressor role of PKCz
in intestinal carcinogenesis via the inhibition of metabolic stress
reprogramming (Ma et al., 2013), as well as the b-catenin and
Yap pathways in ISCs (Llado et al., 2015). In contrast, PKCl/i
has been proposed by others to be a tumor promoter (Justilien
et al., 2014). However, the recently reported analysis of PKCmu-
tations identified in human cancers strongly suggested that most
of thesemutations led to loss of function and nonewould result in
a gain-of-function phenotype (Antal et al., 2015). These studiess 16, 3297–3310, September 20, 2016 ª 2016 The Author(s). 3297
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
are in good agreement with our data demonstrating that PKCz is
a tumor suppressor in several types of neoplasia, including intes-
tinal cancer (Galvez et al., 2009; Kim et al., 2013; Ma et al., 2013),
but they are at odds with the pro-tumorigenic role of PKCl/i pro-
posed by others (Murray et al., 2004).
However, when considering cancer etiology and progression,
cross-talk between the tumor cells and the surroundingmicroen-
vironment must be taken into account. In this regard, the etiology
of intestinal cancer is complex, because disruption of the epithe-
lial barrier, even under conditions in which inflammation is not the
driver of the carcinogenic process, or as consequence of its
erosion during IBD, inevitably results in the hyperproduction of
inflammatory cytokines that enhance tumor progression (Griven-
nikov et al., 2012; Karin and Clevers, 2016). Therefore, at least in
intestinal carcinogenesis, and most likely in all tumors, the exis-
tence of activating or inactivating mutations in a given gene
should be put in the context of other factors driving the inflam-
matory and immunological landscape of the tumor. In this paper,
we have established the role of PKCl/i in the intestinal epithe-
lium, and especially Paneth cells, in inflammation and cancer.
RESULTS
Paneth Cell Defects in PKCl/i-Deficient Intestinal
Epithelial Cells
PKCl/i is widely expressed in the small intestine and colon, as
determined by immunoblot analysis of IECs (Figure 1A), which
suggested a role for PKCl/i in regulating homeostasis in the
gastrointestinal tract. Although all IECs of the small intestine
and colon expressed PKCl/i, its levels were much higher in
Paneth cells at the crypt base (Figures 1B and S1A). This was
confirmed by double immunofluorescence (IF) analysis of intes-
tinal crypts in which we found an almost complete colocalization
of PKCl/i with lysozyme (Lyz), a well-established marker of
Paneth cells (Figures 1C and S1B). To investigate the potential
role of PKCl/i in intestinal homeostasis, we crossed Prkcifl/fl
mice with Villin-cre mice to generate a mouse line lacking
PKCl/i specifically in IECs (PrkciIEC-KO mice). PrkciIEC-KO mice
were born at the expected Mendelian ratios and developed nor-
mally. Epithelial PKCl/i deficiency had no effect on the overall
structures of the ileum or the colon, and it is unlikely that this
was due to compensation, because expression of other PKCs
was not altered in PrkciIEC-KO crypts (Figure S1C). However, we
detected enlargement of the crypts and a severe reduction in
the number of Paneth cells, as identified by the absence of
granule-containing cells in H&E-stained sections and a strong
reduction in Lyz staining in the mutant mice (Figures 1D–1F).
This was also accompanied by the presence of mislocalized
Lyz+ cells in the upper crypt and villi of PrkciIEC-KO intestines (Fig-
ures 1E and 1G). Staining of markers of other differentiated cell
populations did not show alterations in PrkciIEC-KO mice (Fig-
ure S1D). Electron microscopy (EM) analysis also showed loss
of mature Paneth cells in PrkciIEC-KO crypts and revealed alter-
ations in the morphology of the remaining Paneth cells, which
displayed reduced numbers of granules (Figures 1H and 1I).
Further analysis by Lyz staining showed that in contrast to
normal Paneth cells in which Lyz is packaged efficiently in the
granules, in PrkciIEC-KO mice, there was an increase in Paneth3298 Cell Reports 16, 3297–3310, September 20, 2016cells with reduced numbers of Lyz-containing granules and
with diffuse Lyz staining (Figures 1J and 1K). Consistently,
PrkciIEC-KO crypts showed decreased expression of Paneth
cell-related gene transcripts (Figure 1L). Furthermore, genome-
wide transcriptomic analysis identified downregulation of defen-
sin transcripts in the PKCl/i-deficient crypts (Figures 1M). These
results suggest that PKCl/i deficiency in IECs caused a disrup-
tion of Paneth cell homeostasis.
PKCl/i Deficiency Increases Intestinal Epithelial Cell
Death
Histological analysis of PrkciIEC-KO intestines showed a large
number of dying cells with pyknotic nuclei at the crypt and
increased numbers of apoptotic cells positive for cleaved cas-
pase-3 and TUNEL, as compared to Prkcifl/fl intestines, in
which apoptotic cells were mostly detected only at the villus
tip (Figures 2A–2D, S2A, and S2B). EM sections also revealed
increased numbers of dead cells, including necrotic cells, in
PrkciIEC-KO intestines, accompanied by infiltration of macro-
phages that engulfed dead cells (Figures 2E and 2F). Double IF
of Lyz and TUNEL showed that most of the few remaining Paneth
cells in the crypts of PrkciIEC-KO mice were TUNEL positive (Fig-
ures 2G and S2C), suggesting that immature PKCl/i-deficient
Paneth cells also underwent cell death under basal conditions.
Crypt apoptosis was also detected in the colon of PrkciIEC-KO
mice (Figure S2D). NextBio analysis of the upregulated genes
in the PrkciIEC-KO crypts showed a strong correlation with the
Gene Ontology (GO) category ‘‘positive regulation of pro-
grammed cell death’’ (Figure 2H). These results demonstrate
that PKCl/i loss not only results in defective Paneth cells but
also sensitizes crypt cells to apoptosis. Therefore, we next
focused our attention on the molecular mechanisms whereby
PKCl/i regulates crypt cell survival. Interestingly, gene set
enrichment analysis (GSEA) identified ‘‘AP1_pathway’’ as a
significantly upregulated category in PrkciIEC-KO crypts (Fig-
ure 2I). JNK activation is a major component of the AP1-driven
cell death cascades (Davis, 2000). Interestingly, the staining of
p-JNK and p-c-Jun was dramatically increased in the crypts of
PrkciIEC-KO mice as compared to Prkcifl/fl mice (Figure 2J). Immu-
noblot analysis of crypts confirmed increased JNK and caspase-
3 activity associated with PKCl/i deficiency (Figure 2K). Since
JNK is activated by tumor necrosis factor (TNF), we hypothe-
sized that PKCl/i deletion would sensitize IECs to TNF, which
would further increase JNK activation and cell death, thus
creating an amplifying loop resulting in increased inflammation.
In keeping with this concept, when crypt organoid cultures
from PrkciIEC-KO mice were treated with TNF or interferon-g
(IFN-g), two cytokines highly abundant in the intestinal inflamma-
tory milieu, the result was enhanced JNK activation and
concomitant elevation of cleaved caspase-3 (Figure 2L). To
test whether this was a cell-autonomous effect, we used
SW480 as a model system of human intestinal epithelial cells.
Basal JNK activation was highly upregulated in SW480 cells in
which PKCl/iwas knocked down by small hairpin RNA (shRNA),
which was further enhanced by TNF (Figure 2M). To establish the
role of JNK activation in apoptosis triggered by PKCl/i defi-
ciency, PKCl/i-knockdown cells were treated with a cell-perme-
able potent and selective dual ATP and substrate mimetic JNK
Figure 1. Severe Alteration of Paneth Cells in PKCl/i-Deficient Intestinal Epithelia
(A) Immunoblot analysis of PKCl/i in IECs fromdifferent intestinal regions ofPrkcifl/fl andPrkciIEC-KOmice (n = 3): duodenum (D), jejunum (J), ileum (I), and colon (C).
(B) IHC for PKCl/i of small intestine and colon sections (n = 6). Scale bars, 50 mm.
(C) Double IF for PKCl/i (green) and lysozyme (Lyz; red) of small intestine (n = 3). Scale bar, 50 mm.
(D) H&E staining of small intestine sections from Prkcifl/fl and PrkciIEC-KO mice (n = 6). Red arrows point to granule-containing Paneth cells. Scale bars, 50 mm.
(E) IHC for Lyz in small intestine from Prkcifl/fl and PrkciIEC-KO mice (n = 6). Red arrow shows mislocalized Paneth cells. Scale bars, 50 mm.
(F) Quantification of Paneth (Lyz+) cells per crypt in Prkcifl/fl and PrkciIEC-KO mice (n = 6).
(G) Quantification of mislocalized Paneth cells per crypt-villus unit in Prkcifl/fl and PrkciIEC-KO mice (n = 6).
(H) EM images showing reduced number of healthy granules in Paneth cells in the ileum crypts of PrkciIEC-KO mice as compared to those in Prkcifl/fl mice (n = 3).
Scale bar, 10 mm.
(I) Quantification of the number of granules per Paneth cell counted in EM images.
(J) IF for Lyz (red) in Prkcifl/fl and PrkciIEC-KO ileum crypts. Scale bar, 10 mm.
(K) Quantification of the percent of Paneth cell phenotypes (granule numberR 6, granule number < 6, or diffuse granule staining) counted in confocal microscopy
images (n = 30).
(L) qRT-PCR analysis of mRNA levels of Paneth cell-related genes in crypts of Prkcifl/fl and PrkciIEC-KO mice (n = 9).
(M) Heatmap of genome-wide transcriptomic analysis of crypts from PrkciIEC-KO mice as compared to Prkcifl/fl controls (n = 3).
Results are shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001. See also Figure S1.
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Figure 2. PKCl/i Deficiency Increases Intestinal Epithelial Cell Death through JNK Activation
(A) IHC for cleaved caspase-3 (C-Casp3) in Prkcifl/fl and PrkciIEC-KO small intestinal crypts. (n = 3). Scale bar, 50 mm.
(B) Quantification of the number of C-Casp3-positive cells per crypt.
(C) IF for TUNEL (red) of small intestinal sections (n = 3). White dashed line marks the crypt base. Scale bar, 50 mm.
(D) Quantification of the number of TUNEL-positive cells per crypt.
(E) EM images showing a number of dead cells (black circles and top, right) in the ileum crypts of PrkciIEC-KO mice (n = 3). Infiltrating macrophage engulfed the
dead cells (right, bottom). Scale bars, 10 mm.
(F) Quantification of the number of dead cells per crypt.
(legend continued on next page)
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inhibitor termed 126F4. Pre-incubation of PKCl/i-deficient cells
with 126F4 rescued the increased apoptosis (Figures 2N and
S2E). 126F4, like the previously reported DJNKI-1 (Barr et al.,
2002; Bonny et al., 2001), attenuates JNK activation by interact-
ing with the JIP binding site that is essential for both substrate
recognition and activation of JNK by upstream kinases (Barr
et al., 2002; Bonny et al., 2001; Stebbins et al., 2008). Further-
more, ex vivo cultures of PrkciIEC-KO organoids formed in
lower numbers, were smaller and less complex than Prkcifl/fl
organoids, and displayed impaired viability (Figures 2O and
S2F–S2H), which was rescued by incubation with 126F4 (Fig-
ure 2O), but no effect on Lyz expression was observed (Fig-
ure 2P). Collectively, these results demonstrate that the loss of
PKCl/i in the intestinal epithelium results in impaired Paneth
cell homeostasis associated with increased JNK activity and
apoptosis of IECs.
Loss of PKCl/i in the Intestinal Epithelium Results in
Increased Inflammation
Paneth cells provide a first line of defense in the epithelial barrier
by secreting antimicrobial peptides, which are important for pro-
tection against intestinal inflammation (Adolph et al., 2013). This,
together with enhanced IEC apoptosis due to increased JNK ac-
tivity, results in intestinal inflammation. Indeed, NextBio analysis
of genes downregulated inPrkciIEC-KO crypts revealed significant
correlations with the GO terms ‘‘defense response’’ and ‘‘MHC
class II antigen presentation’’ (Figure 3A). We also found sponta-
neous intestinal inflammation with bowel mucosa thickening and
increased immune cell infiltration in the small intestines of
PrkciIEC-KO mice, accompanied by increased expression of in-
flammatory cytokines (Figures 3B–3D). Histological analysis of
colonic sections of PrkciIEC-KO mice showed overall mild inflam-
mation with focal areas of immune cell infiltration and microab-
scess and increased cytokine expression (Figures S3A–S3C).
To investigate whether PKCl/i deficiency sensitizes mice to
experimental inflammation in the large intestine, we subjected
PrkciIEC-KO and control mice to dextran sodium sulfate (DSS).
PrkciIEC-KO mice lost significantly more weight than Prkcifl/fl
controls, concomitantly displaying colonic shortening with
epithelial destruction and extensive intestinal ulceration (Figures
3E–3G). Reduced Ki67 staining was found in PrkciIEC-KO colonic
sections, suggesting a defect in the regenerative response
(Figure 3G). These results indicate that the loss of PKCl/i in
the intestinal epithelium rendersmice highly susceptible to spon-(G) Double IF for TUNEL (red) and Lysozyme (Lyz; green) in Prkcifl/fl and PrkciIEC-
(H) NextBio analysis of genes differentially expressed in PrkciIEC-KO intestinal cryp
regulation of programmed cell death.’’
(I) GSEA enrichment in ‘‘PID AP1 Pathway’’ in crypts from Prkcifl/fl and PrkciIEC-K
(J) IHC for p-JNK or p-c-Jun of small intestine sections from Prkcifl/fl and PrkciIEC
(K) Immunoblot using antibodies against indicated crypt proteins in Prkcifl/fl and
(L) Immunoblot of small intestinal organoids from Prkcifl/fl and PrkciIEC-KOmice usin
TNF-a or IFN-g for 8 hr before collection.
(M) SW480 shNT and shPKCl/i cells were stimulated with TNF-a and analyzed b
(N) SW480 shNT and shPKCl/i cells were preincubated with DMSO or JNK inh
analyzed by immunoblot.
(O and P) Representative pictures and quantification of small intestinal organoids
qRT-PCR analysis of mRNA level of Lyz in organoids (n = 3) (P). Scale bar, 100 m
Results are shown as mean ± SEM. *p < 0.05, **p < 0.01. See also Figure S2.taneous ileitis as well as spontaneous and experimentally
induced colitis.
Because deregulation of intestinal homeostasis and suscepti-
bility to inflammation are often associated with alterations in the
commensal bacterial population, we investigated the extent to
which bacterial communities were altered in PrkciIEC-KO mice.
Analysis of PrkciIEC-KO mice revealed alterations in the micro-
biota composition, with increased abundance of Proteobacteria
and reduction in Firmicutes (Figures 3H and S3D). Importantly,
this observed dysbiosis in PrkciIEC-KO mice is consistent with
that reported in human IBD patients (Frank et al., 2007). Differ-
ences in microbiota distributions were more pronounced after
DSS treatment, with PrkciIEC-KO mice also showing alterations
in Deferribacteres and Bacterioidetes (Figures 3H and S3D).
These data suggest that alterations in Paneth cell and increased
IEC apoptosis upon PKCl/i deficiency promote intestinal inflam-
mation through the loss of the mucosal barrier and by modifica-
tion of the microbiota composition accompanied by bacterial
translocation.
PKCl/i Deficiency Promotes Tumorigenesis via
Increased Inflammation and Dysbiosis
Because inflammation is a well-established promoter of intesti-
nal tumorigenesis, we tested whether the loss of PKCl/i in the
intestinal epithelium could contribute to intestinal cancer. Of
note, previously published data suggested that PKCl/i loss in
the intestinal epithelium resulted in impaired tumorigenesis in
ApcMin/+ mice (Murray et al., 2009). This is counterintuitive with
the tumor promoter role of inflammation and the pro-inflamma-
tory phenotype of PrkciIEC-KO mice. To address this question,
we crossed PrkciIEC-KO mice with Apcfl/fl mice to generate
Apcfl/+;PrkciIEC-KO mice. Interestingly, Apcfl/+;PrkciIEC-KO mice
developed more and larger tumors than Apcfl/+ control mice in
both the small intestine and colon (Figures 4A and 4B). Histolog-
ical analysis revealed that tumors from Apcfl/+;PrkciIEC-KO mice
were often accompanied by ulceration, with a concomitant in-
crease in proliferation and cell death (Figures 4A–4D). Notably,
PKCl/i-deficient tumors also showed increased expression of
inflammatory cytokines (Figure 4E), indicating that the increased
tumorigenesis could be related to the pro-inflammatory environ-
ment created by the lack of PKCl/i. To further test this hypoth-
esis, we used a colitis-associated CRC model that combines
the carcinogen azoxymethane (AOM) and DSS. AOM-DSS-
treated PrkciIEC-KO mice developed more and larger tumorsKO small intestine. White dashed line marks the crypt base. Scale bar, 50 mm.
ts and Prkcifl/fl controls. Gene signatures corresponding to GO terms ‘‘Positive
O mice using C2 MSigDB database.
-KO mice. (n = 3). Scale bar, 50 mm.
PrkciIEC-KO mice.
g indicated antibodies. Organoids from each genotype were treated with either
y immunoblot at indicated time points.
ibitor (126F4), stimulated with TNF-a and cycloheximide (CHX) for 4 hr, and
from Prkcifl/fl and PrkciIEC-KO mice cultured with or without 126F4 for 3 days (O).
m.
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Figure 3. Loss of PKCl/i in the Intestinal
Epithelium Results in Increased Inflammation
(A) NextBio analysis of genes differentially ex-
pressed in PrkciIEC-KO intestinal crypts and Prkcifl/fl
controls. Venn diagrams show the number of com-
mon and unique genes in both sets. Gene signatures
corresponding to GO terms ‘‘defense response’’ and
‘‘MHC protein complex.’’
(B) H&E staining of Prkcifl/fl and PrkciIEC-KO small
intestines (n = 6). Red arrows point to immune cell
infiltrates.
(C) IF staining for CD45, Gr-1, or F4/80 inPrkcifl/fl and
PrkciIEC-KO small intestinal sections (n = 3).
(D) qRT-PCR analysis of mRNA levels of inflamma-
tory cytokines in ileum crypts of Prkcifl/fl and
PrkciIEC-KO mice (n = 6).
(E–G) Percentage of change in body weight (E),
representative pictures and quantification of colon
length (F), and H&E and Ki67 staining (G) of Prkcifl/fl
and PrkciIEC-KO colon sections (n = 4) subjected to a
DSS-induced colitis model.
(H) Phylum-level analysis of microbiota by 16SrDNA
pyrosequencing of fecal pellets at basal conditions
and after DSS treatment in Prkcifl/fl and PrkciIEC-KO
mice (n = 8). Scale bars, 50 mm.
Results are shown as mean ± SEM. *p < 0.05,
**p < 0.01. See also Figure S3.than identically treated Prkcifl/fl mice, which also displayed
higher rates of proliferation and cell death (Figures S4A–S4D).
Collectively, these results are consistent with a model whereby
the loss of PKCl/i in the intestinal epithelium impairs Paneth
cell function and increases IEC apoptosis, resulting in barrier
disruption, commensal infiltration, and severe inflammation,
which promotes intestinal tumorigenesis. To rigorously test this
hypothesis,weadministeredacocktail of broad-spectrumantibi-
otics to mice of both genotypes and determined the effect on tu-
mor development. Interestingly, antibiotic treatment impaired the
increased tumorigenesis phenotype of Apcfl/+;PrkciIEC-KO mice,
which showed a reduction in the number and size of tumors
compared to untreated mice (Figures 4F and 4G). This effect
was accompanied by a decrease in Tnf expression (Figure 4H).
Similar results were obtained when the colons of these mice
were analyzed (Figures S4F–S4H). These results established
that antibiotic treatment diminished the pro-tumorigenic inflam-
matory conditions of PKCl/i-deficient intestines, supporting a3302 Cell Reports 16, 3297–3310, September 20, 2016role for PKCl/i as a non-cell-autonomous
tumor suppressor in inflammation-induced
intestinal tumorigenesis. Importantly, the
reduction in inflammation and cell death
promoted by antibiotic treatment did not
restore Paneth cells to normal levels in
Apcfl/+;PrkciIEC-KO mice (Figures 4I, 4J,
and S4E). This demonstrated that PKCl/i
deficiency in the intestinal epithelium re-
sults in defects in Paneth cell homeostasis
independent of cell death and the presence
of inflammation in the crypt microenviron-
ment. This is in agreement with data in Fig-ures 2O and 2P demonstrating that JNK inhibition in organoids
rescued cell death, but not Paneth cell differentiation defects.
PKCl/i-Deficiency Impairs Paneth Cell Differentiation
through Atoh1
Because PKCl/i’s effects on Paneth cell differentiation and
intestinal homeostasis were not a consequence of increased
cell death, we next asked whether Paneth cell defects in
PrkciIEC-KO mice were actually due to impaired differentiation
or to defective maintenance. To address this question, we char-
acterized Paneth cell alterations in PrkciIEC-KO mice by double
staining for Lyz and Alcian blue (AB), a marker of goblet cells.
While in Prkcifl/fl intestines Lyz expression is localized in the crypt
base and does notmerge with AB, in PrkciIEC-KO intestines, a sig-
nificant number of Lyz+ cells were found in the villus and upper
crypt co-stained for Lyz and AB (Figures 5A and 5B). These
data suggest that PKCl/i deficiency leads to a failure of intestinal
secretory progenitor cells to properly differentiate into Paneth
(legend on next page)
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cells and to default to an intermediate goblet cell-like phenotype.
In keeping with this hypothesis, the expression levels of Atoh1
and Gfi1 were lower in the crypts from PrkciIEC-KO mice (Fig-
ure 5C). Atoh1 and Gfi1 are critical transcription factors for the
differentiation of Paneth cells (Shroyer et al., 2005; Yang et al.,
2001). To test whether PKCl/i might also regulate Paneth cell
maintenance or survival after differentiation, we crossed Prkcifl/fl
mice with a Defa6-cre mouse line (Adolph et al., 2013) to create
PrkciPC-KO, in which PKCl/i is selectively deleted in terminally
differentiated Paneth cells. We confirmed the exclusive expres-
sion of this Cre line in Paneth cells by crossing with the Rosa-
LacZ reporter (Figure S5A). Deletion of PKCl/i in PrkciPC-KO
Paneth cells was also verified by double staining of PKCl/i
and Lyz (Figure S5B). Importantly, no defects were found in
Paneth cell numbers or Lyz content in PrkciPC-KO mice (Figures
S5C–S5E). Of note, these mice did not show spontaneous enter-
itis or increased sensitivity to colitis (Figures S5F–S5H). These
results strongly suggest that PKCl/i is important for proper
Paneth cell differentiation, but not for Paneth cell maintenance
or survival, in terminally differentiated cells.
A critical event in Paneth cell differentiation is Notch inactiva-
tion in precursor cells (Fre et al., 2005; van Es et al., 2005; Yin
et al., 2014) (Figure 5D). We next determined whether inactiva-
tion of Notch signaling could rescue the defect in Paneth cell dif-
ferentiation caused by PKCl/i deficiency. For this, we incubated
organoids of both genotypes with DAPT, a selective and widely
used g-secretase inhibitor of the Notch pathway (Dovey et al.,
2001; Yin et al., 2014). Interestingly, incubation with DAPT led
to a robust induction of Lyz in Prkcifl/fl, but not PrkciIEC-KO, orga-
noids (Figure 5E). The same results were obtained when the
levels of Defa6, another marker of Paneth cell differentiation, or
those of goblet (Muc2) or enteroendocrine (Chga) cells were
determined (Figures 5E and 5F). In contrast, Alpi, which is a
marker of enterocytes, was not affected by DAPT treatment of
PKCl/i-deficient organoids (Figure 5F). Notably, the addition
of DAPT did not activate the expression of either Atoh1 or Gfi1
in PKCl/i-deficient organoids, although it induced a robust
response in Prkcifl/fl organoids (Figure 5G). Collectively, these
results demonstrate that PKCl/i is required for Paneth cell differ-
entiation, most probably through the control of the transcrip-
tional regulation of Atoh1 and Gfi1 upon Notch inactivation.
Epigenetic Control of Atoh1 Expression by PKCl/i
GSEA of the transcriptomic experiment described above
provided an important clue in understanding the precise mecha-Figure 4. Increased Inflammation and Dysbiosis Induced by PKCl/i De
(A) Macroscopic images and H&E staining of tumors (red dashed circles) in sma
(B) Quantification of the total tumor numbers and stratification of tumor numbers
(C) Double IF for TUNEL (red) and Ki67 (green) in small intestine tumors of Apcfl/
(D) Quantification of the number of TUNEL- or Ki67-positive cells per field.
(E) qRT-PCR analysis of inflammatory cytokine mRNA levels in small intestinal tu
(F) H&E staining of small intestine from Apcfl/+ and Apcfl/+;PrkciIEC-KO mice with o
(G) Quantification of the number of all tumors (left) or large tumors (right; size >
treatment (n = 5–7).
(H) qRT-PCR analysis of Tnf mRNA levels in the tumors of Apcfl/+ and Apcfl/+;Prk
(I) Double IF for lysozyme (Lyz; green) and TUNEL (red) in non-tumor lesions of A
(J) Quantification of the number of Lyz-positive Paneth cells and TUNEL-positive
Results are shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.
3304 Cell Reports 16, 3297–3310, September 20, 2016nisms whereby PKCl/i regulates Atoh1 expression. Interest-
ingly, a category that was also significantly upregulated in
PKCl/i-deficient crypts was ‘‘SUZ12_TARGETS’’ (Figure 6A).
SUZ12 is a critical component of the polycomb repressive com-
plex 2 (PRC2), which is well known for its ability to repress cell
differentiation and regulate self-renewal in embryonic stem cells
via histone methylation to produce H3K27me3 (Margueron and
Reinberg, 2011). We hypothesized that epigenetic modifications
controlled by PKCl/i could regulate Atoh1 expression. Impor-
tantly, ENCODE interrogation of the regulatory region of both
Atoh1 and Gfi1 genes revealed the potential for recruitment of
SUZ12 and EZH2, the enzymatic subunit of the PRC2 complex,
along with the repression marker H3K27me3 (Figure 6B).
Conceivably, PKCl/i could influence PRC2 activity to control
Atoh1 expression. To test this possibility, we performed chro-
matin immunoprecipitation (ChIP) analysis in crypts from Prkcifl/fl
and PrkciIEC-KO mice and found that both Atoh1 and Gfi1 regula-
tory regions were highly occupied by EZH2, which correlated
with enrichment of the repressionmarker H3K27me3 (Figure 6C).
Immunoblot analysis demonstrated increased levels of EZH2 in
PKCl/i-deficient crypts (Figure 6D). Similar results were ob-
tained when the levels of EZH2 were determined in 293 cells in
which PKCl/i had been knocked out by clustered regularly inter-
spaced short palindromic repeats (CRISPR)/Cas9 gene editing
(Figure 6E). Notably, double IF analysis of intestinal samples
from both mouse genotypes showed a strong accumulation of
H3K27me3 and EZH2 signals in the crypts of PrkciIEC-KO mice
(Figure 6F).
In vitro kinase assay using purified hemagglutinin (HA)-tagged
EZH2 and recombinant PKCl/i demonstrated that PKCl/i
robustly phosphorylated EZH2 (Figure 6G). To map the PKCl/i
phosphorylation sites in EZH2, we used titanium dioxide (TiO2)-
based phosphopeptide enrichment on enzymatic digests of
in vitro phosphorylation reactions followed by high-performance
liquid chromatography tandem mass spectrometry (MS/MS)
analysis. Using this approach, we identified T487 as a major
PKCl/i phosphorylation site and several sites of low abundance
such as S690 and T345 (Figure S6). T487 and T345 are reported
as sites important for protein degradation (Wu and Zhang,
2011). This suggests that PKCl/i might control EZH2 protein
stability. Consistently, EZH2 was significantly more stable in
cycloheximide-treated PKCl/i-deficient cells (Figure 6H). These
data strongly suggest that loss of EZH2 phosphorylation upon
PKCl/ideficiency increasesEZH2stability andH3K27me3 levels,
which represses Atoh1 and Gfi1 expression and Paneth cellficiency Promotes Tumorigenesis
ll intestine or colon from Apcfl/+ and Apcfl/+;PrkciIEC-KO mice (n = 10).
according to size (n = 10).
+ and Apcfl/+;PrkciIEC-KO mice (n = 3).
mors from Apcfl/+ and Apcfl/+;PrkciIEC-KO mice (n = 6).
r without antibiotic treatment (n = 5). Black arrows point to tumors.
2 mm) in Apcfl/+ and Apcfl/+;PrkciIEC-KO mice with or without antibiotic (Abx)
ciIEC-KO small intestine (n = 6).
pcfl/+ and Apcfl/+;PrkciIEC-KO small intestine (n = 3).
cells per crypt. Scale bars, 50 mm.
001. See also Figure S4.
Figure 5. PKCl/i Deficiency Impairs Paneth Cell Differentiation through Atoh1
(A) Alcian blue (AB) and lysozyme (Lyz) staining of small intestine sections from Prkcifl/fl and PrkciIEC-KO mice (n = 5).
(B) Quantification of AB and Lyz staining per area.
(C) qRT-PCR analysis of Atoh1 and Gfi1 mRNA levels in small intestinal crypts from Prkcifl/fl and PrkciIEC-KO mice (n = 4).
(D) Diagram of IEC differentiation.
(E–G) qRT-PCR analysis of Paneth cell markers (E), other intestinal epithelial differentiation marker mRNA levels (F), or secretory cell transcriptional factors (G) in
crypt organoids either untreated (Ctrl) or treated with DAPT for 3 days (n = 4). Scale bars, 50 mm.
Results are shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001. See also Figure S5.differentiation. In support of this model, treatment with GSK126,
an inhibitor of EZH2activity, resulted in upregulationof thePaneth
cell population in PrkciIEC-KO organoids (Figure 6I). Collectively,
these results demonstrate that PKCl/i is required for Paneth
cell differentiation through the regulation of PRC2 activity and
that this event is necessary to allow Atoh1 and Gfi1 transcription.
PKCl/i Is Expressed in Human Intestinal Paneth Cells,
and Its Expression Decreases with Progression of
Crohn’s Disease
Paneth cell dysfunction and ileal inflammation have been linked
to the etiology of IBD (Cadwell et al., 2008). Therefore, to inves-tigate the relevance of PKCl/i to Paneth cell function in human
patients, we used immunohistochemistry (IHC) for PKCl/i to
analyze 40 ileum tissue sections derived from patients with
CD. Expression of PKCl/i was first determined in normal mu-
cosa from uninvolved proximal margins containing little or no
inflammation. Importantly, PKCl/i staining strongly localized
with that of Lyz, as demonstrated by double IF (Figure S7A).
This indicated that PKCl/i expression, similar to our findings in
mice, was enriched in human Paneth cells. To study the expres-
sion of PKCl/i upon disease progression, samples were subdi-
vided by a pathologist, blinded to sample origins, into different
categories (mild, moderate, and severe) according to theCell Reports 16, 3297–3310, September 20, 2016 3305
(legend on next page)
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severity of inflammation in the intestinal mucosa. Notably, there
was a gradual reduction in PKCl/i with CD progression, with
minimal expression in the most severe group (Figures 7A and
7B). Furthermore, active inflammatory lesions in the intestinal
samples of CD patients showed that low PKCl/i/Lyz+ cells
were not restricted to the crypt base and displayed a disorga-
nized and diffuse pattern of Lyz expression not confined to the
granule, as opposed to that in normal mucosa (Figures 7C,
top, and S7A). In addition, a large number of TUNEL-positive
cells were observed in the crypts of active lesions correlating
with low PKCl/i expression (Figure 7C, bottom). Interestingly,
double Lyz and AB staining of moderate-to-severe CD patients
demonstrated a large number of mislocalized immature Paneth
cells that were positive for both Lyz and AB (Figure 7D). These
findings suggest a defect in Paneth cells in CD samples similar
to that observed in PrkciIEC-KO mice. Likewise, CD crypts with
low PKCl/i levels showed enhanced expression of H3K27me3
similar to the phenotype of PKCl/i-deficient mice (Figure 7E).
To expand on these observations, we analyzed PRKCImRNA
expression in public gene datasets of CD and UC. Consistent
with the results of the IHC of CD samples, PKCl/i was signifi-
cantly downregulated in CD and UC samples, as compared to
healthy controls, in all seven datasets analyzed (Figures 7F and
S7B). Furthermore, there was a significant positive correlation
between PRKCI and ATOH1mRNA levels in three different data-
sets of IBD samples (Figure 7G), in agreement with a critical role
for PKCl/i in Paneth cell differentiation through the control of
Atoh1 expression. We next performed GSEA of correlation pro-
files in the IBD clinical dataset (GSE59071) that included the
larger number of samples fromboth CD andUCpatients in which
PRKCImRNAwas downregulated. Analyses with the H compila-
tion of MsigDB (Broad Institute) revealed that PRKCI levels
inversely correlated with gene signatures related to inflammation
(Figures 7H and 7I), consistent with a role for PKCl/i in control-
ling intestinal homeostasis.
Because PKCl/i-deficient mice had an inflammatory and pro-
tumorigenic phenotype, we next investigated the role of PKCl/i
in humanCRC in the context of inflammation. For this, we carried
out a molecular concept map analysis of CRCmicroarray data in
the Oncomine database (Rhodes et al., 2007) using signatures of
PRKCI-correlated or PRKCI-anticorrelated genes derived from
the IBD clinical cohort (GSE59071). A heatmap visualization of
significant comparisons showed a strong overlap of PRKCI-
correlated genes with those underexpressed in colon and colo-Figure 6. PKCl/i Regulates Atoh1 by Controlling EZH2 Phosphorylatio
(A) GSEA of SUZ12 targets in crypts from Prkcifl/fl and PrkciIEC-KO mice using C2
(B) ENCODE schematic of epigenetic marks in ATOH1 gene.
(C) Primer design for ChIP-qPCR analysis of Atoh1 and Gfi1 occupancy of EZH2
antibodies. Co-immunoprecipitated DNA was examined using qPCR with primer
(D and E) Immunoblot analysis of EZH2 in crypt proteins from Prkcifl/fl andPrkciIEC-
(F) Double IF for lysozyme (Lyz; red) and H3K27me3 (top) or EZH2 (bottom) (gree
(G) In vitro phosphorylation of HA-tagged EZH2 immunoprecipitates by baculovi
and immunoblotting for the indicated proteins.
(H) CRISPR/CAS9-mediated 293 PKCl/i-KO or control cells were incubated with c
indicated time points. EZH2 protein levels were normalized to actin (n = 5).
(I) Small intestinal organoids from WT and PrkciIEC-KO mice were cultured and t
Representative pictures and quantification are shown. Scale bars, 25 mm.
Results are shown as mean ± SEM. **p < 0.01. See also Figure S6.rectal tumors versus normal samples in advanced clinical stage
versus earlier stages and in patients with poor versus good prog-
noses (Figure S7C). Accordingly, PRKCI-anticorrelated genes
showed significant overlap with those found to be overex-
pressed in these same categories (Figure S7C). Furthermore,
Kaplan-Meier survival analysis of CRCpatients stratified accord-
ing to PRKCI expression revealed that low PRKCI levels corre-
lated with significantly worse patient survival (Figure 7J). All of
these results support an unanticipated role of PRKCI as a non-
cell-autonomous tumor suppressor in the context of colon can-
cer associated with inflammation.
DISCUSSION
Alterations in intestinal epithelial homeostasis contribute to
dysbiosis and intestinal inflammation and are clearly involved
in intestinal cancer initiation and progression (Medema and Ver-
meulen, 2011; Peterson and Artis, 2014). Paneth cells are critical
for creating an anti-microbial and nurturing environment that aids
in the survival and function of crypt cells and maintenance of the
intestinal barrier (Clevers and Bevins, 2013; Sato et al., 2011).
Here, we show that PKCl/i is expressed in the whole intestinal
epithelium and prominently in Paneth cells and demonstrate
that it plays a dual role by promoting Paneth cell differentiation
and the survival of crypt cells. Thus, PKCl/i deficiency, by im-
pairing Paneth cell differentiation, triggers an inflammatory
response that is further amplified by increased apoptosis in the
whole intestinal epithelium both in the small intestine and colon,
and that is driven by themicrobiota. Importantly, we also showed
that human CD patients displayed reduced PKCl/i levels that
correlated with impaired Paneth cell development, IEC death,
and intestinal inflammation.
Germane to these observations is the fact that PKCl/i is
required, in a cell-autonomousmanner, for the optimal transcrip-
tional activation of the two master regulators of Paneth cell
differentiation, Atoh1 and Gf1, through their epigenetic control
upon Notch inactivation. This explains why the phenotype of
PrkciIEC-KO shared some characteristics with Atoh1 and Gfi1
knockout (KO) mice (Shroyer et al., 2005, 2007; Yang et al.,
2001). In this regard, Atoh1 KO mice display a complete loss of
all secretory lineages, whereas Gfi1 KO mice only have a partial
reduction in the number of Paneth and goblet cells, with a
concomitant increase in enteroendocrine cells (Shroyer et al.,
2005, 2007; Yang et al., 2001). In contrast, PrkciIEC-KO mice,n and Stability
MSigDB database.
and H3K27me3. ChIP assay was performed with anti-EZH2 or anti-H3K27me3
s specific for the Atoh1 or Gfi1 regulatory region (n = 3).
KOmice (D) or 293 PKCl/i-KO cells generated by the CRISPR/CAS9 system (E).
n). White dashed line marks the crypt base (n = 3).
rus-expressed recombinant PKCl/i with ATPgS followed by PNBM alkylation
ycloheximide (CHX) and protein stability was determined by immunoblotting at
reated with or without GSK126 for 5 days and analyzed by IF for Lyz (n = 4).
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Figure 7. PKCl/i Levels Are Downregulated in Clinical Samples from Inflammatory Bowel Disease Patients
For a Figure360 author presentation of Figure 7, see http://dx.doi.org/10.1016/j.celrep.2016.08.054#mmc3
(A) IHC for PKCl/i in ileum sections from patients with CD. Subgroups were assigned according to severity of the disease (n = 10 for each subgroup). Scale
bars, 50 mm.
(B) Quantification of PKCl/i-positive cells per area or per crypt of tissue sections in (A).
(C) Double IF for lysozyme (top; Lyz, red) or TUNEL (bottom; red) and PKCl/i (green)White arrowheads point to TUNEL-positive cells.White dashed linemarks the
crypt base (n = 3). Scale bars, 25 mm.
(D) Double staining for Alcian blue (AB) and Lyz in ileum sections from patients with CD (n = 3). Red arrowheads point the colocalization of AB and Lyz. Scale
bars, 50 mm.
(E) Double IF for PKCl/i (red) and H3K27me3 (green) in ileum sections of patients with CD (n = 3). White dashed line marks the crypt base. Scale bars, 25 mm.
(F) PRKCI mRNA levels in IBD patient samples. Data were collected from public datasets of gene expression.
(G) Pearson correlation analysis of gene expression between ATOH1 and PRKCI in three different IBD datasets.
(H) GSEA of the correlation profile for PRKCI in an IBD clinical cohort (GSE59071) using the ‘‘Hallmarks’’ compilation from Molecular Signature Database
(MSigDB, Broad Institute).
(legend continued on next page)
3308 Cell Reports 16, 3297–3310, September 20, 2016
although dramatically affecting the levels of mature Paneth cells,
did not show their complete ablation, consistent with the fact
that PKCl/i inactivation resulted in the reduction, but not com-
plete loss, of Atoh1 and Gfi1 expression. Furthermore, proof
that Paneth cell defects are not secondary to the increased
sensitivity of IECs to apoptosis or inflammation is that inhibition
of JNK activity in organoid cultures rescued the increased
apoptosis associated with PKCl/i ablation but did not rescue
the defect in Paneth cell differentiation. Likewise, antibiotic treat-
ment did not restore normal Paneth cell homeostasis in vivo,
although it completely abolished intestinal inflammation, which
is in keeping with the notion that PKCl/i is a cell-autonomous
epigenetic regulator of Paneth cell differentiation. Interestingly,
treatment of PKCl/i-deficient organoids with a pharmacological
PRC2 inhibitor fully normalized Paneth cell levels. Therefore, we
propose here that epigenetic modification drugs, such as EZH2
inhibitors, could be a valid therapeutic strategy for IBD and intes-
tinal cancer.
In this regard, our results also have important implications
beyond the biology of intestinal inflammation and resolve an
important conundrum in the PKC field by definitively establishing
a non-cell-autonomous tumor suppressor role for PKCl/i in in-
testinal carcinogenesis. Intriguingly, previous data suggested
that loss of PKCl/i in the intestinal epithelium prevented tumor-
igenesis in theApcMin/+ mousemodel (Murray et al., 2009), which
correlated with more inflammation in the DSS model (Calcagno
et al., 2011). These were paradoxical results if it is taken into
consideration that inflammation is a tumor-promoter state and
a risk factor for intestinal cancer in human patients (Karin and
Clevers, 2016). Our results reported here resolve this puzzle by
showing that the loss of PKCl/i in the epithelium results in
more, not less, tumorigenesis. Of note, this effect is detected
both under basal and DSS-induced conditions and, importantly,
is abrogated inmice inwhich themicrobiota has been obliterated
by antibiotic treatment. We suggest that caution should be taken
when considering the pharmacological inhibition of PKCl/i as
an anti-cancer strategy, since it will result in an enhanced risk
of CRC.
EXPERIMENTAL PROCEDURES
A detailed description of the experimental procedures utilized in this work can
be found in Supplemental Experimental Procedures. Primers used are
described in Table S1.
Mice
All mouse strains were generated in a C57BL/6 background. All mice were
born and maintained under pathogen-free conditions. Animal handling and
experimental procedures conformed to institutional guidelines (SBP Medical
Discovery Institute Institutional Animal Care and Use Committee).
CD Patient Samples
Surgically resected specimens were obtained from CD patients who had been
admitted to Hyogo College of Medicine in Japan. Written informed consent(I) Enrichment plot corresponding to ‘‘INFLAMMATORY_RESPONSE’’ gene set o
(J) Kaplan-Meier plot generated by median split of colorectal cancer patients fr
Stanford).
Results are shown as mean ± SEM. **p < 0.01, ***p < 0.005, ****p < 0.001. See awas obtained from patients with the protocol approved by the ethics commit-
tee of Hyogo College of Medicine. De-identified samples were sent to SBP
Medical Discovery Institute and used for histological analyses. The study
was approved by the ethics committee of SBP Medical Discovery Institute.
Statistical Analyses
All the statistical tests are justified for every figure. Data are presented as the
mean ±SEM. Significant differences between groups were determined using a
Student’s t test (two-tailed unpaired) when the data were normally distributed
(D’Agostino test). If the data were not normally distributed, a Mann-Whitney
test was used. The significance level for statistical testing was set at
p < 0.05. All experiments were performed at least two or three times.
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